Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carmen Tur

Showing results (101-110 of 145) with videos related to

Pageof 15
Sort By:
Brain : a Journal of Neurology|April 23, 2015
Defining high, medium and low impact prognostic factors for developing multiple sclerosisMar Tintore, Àlex Rovira, Jordi Río, et al.
Journal of Neurology|November 20, 2021
Correction to: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patientsJordi Río, Àlex Rovira, Claudio Gasperini, et al.
Neurology|October 3, 2022
Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With ImagingRosa Cortese, Ferran Prados Carrasco, Carmen Tur, et al.
Journal of Neurology|October 1, 2021
Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patientsJordi Río, Àlex Rovira, Claudio Gasperini, et al.
Nature Reviews. Neurology|January 13, 2021
Mind the gap: from neurons to networks to outcomes in multiple sclerosisDeclan T Chard, Adnan A S Alahmadi, Bertrand Audoin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 29, 2021
Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosisSusana Otero-Romero, Pere Carbonell-Mirabent, Luciana Midaglia, et al.
JAMA Neurology|December 19, 2022
Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple SclerosisCarmen Tur, Pere Carbonell-Mirabent, Álvaro Cobo-Calvo, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 18, 2023
Evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease courseOmar Abdel-Mannan, Dimitrios Champsas, Carmen Tur, et al.
Lancet (London, England)|May 28, 2026
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b studyGavin Giovannoni, Laura Airas, Riley Bove, et al.
Neurology|September 15, 2021
Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated SyndromeMar Tintore, Alvaro Cobo-Calvo, Pere Carbonell, et al.
Pageof 15

Showing results (101-110 of 145) with videos related to

Sort By:
Pageof 15
Brain : a Journal of Neurology|April 23, 2015
Defining high, medium and low impact prognostic factors for developing multiple sclerosisMar Tintore, Àlex Rovira, Jordi Río, et al.
Journal of Neurology|November 20, 2021
Correction to: Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patientsJordi Río, Àlex Rovira, Claudio Gasperini, et al.
Neurology|October 3, 2022
Differentiating Multiple Sclerosis From AQP4-Neuromyelitis Optica Spectrum Disorder and MOG-Antibody Disease With ImagingRosa Cortese, Ferran Prados Carrasco, Carmen Tur, et al.
Journal of Neurology|October 1, 2021
Treatment response scoring systems to assess long-term prognosis in self-injectable DMTs relapsing-remitting multiple sclerosis patientsJordi Río, Àlex Rovira, Claudio Gasperini, et al.
Nature Reviews. Neurology|January 13, 2021
Mind the gap: from neurons to networks to outcomes in multiple sclerosisDeclan T Chard, Adnan A S Alahmadi, Bertrand Audoin, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|November 29, 2021
Oral contraceptives do not modify the risk of a second attack and disability accrual in a prospective cohort of women with a clinically isolated syndrome and early multiple sclerosisSusana Otero-Romero, Pere Carbonell-Mirabent, Luciana Midaglia, et al.
JAMA Neurology|December 19, 2022
Association of Early Progression Independent of Relapse Activity With Long-term Disability After a First Demyelinating Event in Multiple SclerosisCarmen Tur, Pere Carbonell-Mirabent, Álvaro Cobo-Calvo, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|November 18, 2023
Evolution of brain MRI lesions in paediatric myelin-oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and its relevance to disease courseOmar Abdel-Mannan, Dimitrios Champsas, Carmen Tur, et al.
Lancet (London, England)|May 28, 2026
Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b studyGavin Giovannoni, Laura Airas, Riley Bove, et al.
Neurology|September 15, 2021
Effect of Changes in MS Diagnostic Criteria Over 25 Years on Time to Treatment and Prognosis in Patients With Clinically Isolated SyndromeMar Tintore, Alvaro Cobo-Calvo, Pere Carbonell, et al.
Pageof 15